Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
- 1.1k Downloads
Despite representing a breakthrough in the treatment of immune-mediated rheumatic diseases, the direct costs of biotechnological therapies represent a burden to healthcare budgets worldwide. Furthermore, several studies demonstrated that socioeconomically constrained countries have poorer access to these therapies and this has consequences on the optimal management of rheumatic patients. Experience with small peptide biosimilars like filgrastim and epoetin confirmed significant cost savings but revealed variable market uptake. In this report, we summarize the available budget impact models and discuss possible determinants of the pharmacoeconomic performance of antirheumatic biosimilar drugs.
KeywordsBiosimilars Pharmacoeconomics Antirheumatic agents Rheumatoid arthritis CT-P13
Compliance with Ethical Standards
Conflicts of Interest
FCA reports personal fees from Pfizer, outside the submitted work. JG reports personal fees from Pfizer, Merck, Abbvie, Roche, Celltrion, and Sandoz, outside the submitted work. JEF reports institutional grants from UCB and Pfizer, personal fees from Jansen, Pfizer, Abbvie, MSD, and Roche, and advisory board service for Celgene, Novartis and Hospira, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Accessed 21 Feb 2016.
- 2.European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf. Accessed 21 Feb 2016.
- 3.European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf. Accessed 21 Feb 2016.
- 4.World Health Organisation. Guidelines on evaluation of similar biotherapeutic products. 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 21 Feb 2016.
- 5.U.S. Food and Drug Administration. scientific considerations in demonstrating biosimilarity to a reference product—Guidance for Industry. 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 21 Feb 2016.
- 6.European Medicines Agency. Remsima assessment report. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Accessed 28 Feb 2016.
- 7.Samsung bioepis enters the European biopharmaceutical market with Benepali ®, the First fusion protein biosimilar approved by the European Commission. 2016. http://www.samsungbioepis.com/newsroom2/newsroom_12.html. Accessed 28 Feb 2016.
- 9.U.S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. Accessed 30 April 2016.
- 13.Branco JC, Rodrigues AM, Gouveia N, et al. Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt—a national health survey. RMD Open. 2016;2:e000166. doi: 10.1136/rmdopen-2015-000166.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.•Huscher D, Mittendorf T, von Hinüber U, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis. 2015;74:738–45. This study showed that the increase in treatment costs over the 2002–2011 time period associated with lower hospitalisation rates, better functional status and a lower incidence of work disability, offsetting a large proportion of risen drug costs.CrossRefPubMedGoogle Scholar
- 17.Chevreul K, Haour G, Lucier S, et al. Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation—an economic analysis based on the ESPOIR cohort. PLoS ONE. 2014;9:e97077. doi: 10.1371/journal.pone.0097077.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Philippidis A. The top 25 best-selling drugs of 2014. 2015. http://www.genengnews.com/insight-and-intelligence/the-top-25-best-selling-drugs-of-2014/77900383/?kwrd=top%20selling&page=1. Accessed 20 Feb 2016.
- 19.IMS Institute for Health Informatics. Medicines use and spending shifts. 2015. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Use%20of%20Meds%20-%202015/Spending-on-Specialty-Medicines.pdf. Accessed 20 Feb 2016.
- 20.•IMS Institute for Health Informatics. Global medicines use in 2020. 2015. http://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-medicines-use-in-2020. Accessed 20 Feb 2016. This report provides an outlook on the use and global spending with medicines through 2020 in both developed and pharmerging markets for different types of molecules.
- 23.••Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198–206. This study performed in 46 European countries showed that those with lower income have less access to synthetic and especially biologic DMARDs. Furthermore, the annual price of biological treatment surpassed the GDP in more than half of these countries.CrossRefPubMedGoogle Scholar
- 28.European Medicines Agency. European Public Assessment Reports. 2016. http://www.ema.europa.eu/ema/index.jsp?curl = pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid = WC0b01ac058001d124&searchTab = searchByAuthType&alreadyLoaded = true&isNewQuery = true&status = Authorised&keyword = Enter + keywords&searchType = name&taxonomyPath = &treeNumber = &searchGenericType = biosimilars&genericsKeywordSearch = Submit. Accessed 25 Feb 2016.
- 30.IMS Institute for Health Informatics. Assessing biosimilar uptake and competition in European markets. 2014. https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf. Accessed 12 Mar 2016.
- 32.•Sun D, Andayani T, Altyar A, MacDonald K, Abraham I. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European union G5 countries: a simulation study. Clin Ther. 2015;37:842–57. Using three different models, this study demonstrated significant cost-savings as a result of switching from reference filgrastim and pegfilgrastim to biosimilar filgrastim, as well as additional patients treated with antineoplastic monoclonal antibodies and number of patients needed to convert to provide access to these therapies.CrossRefPubMedGoogle Scholar
- 36.IMS Institute for Health Informatics. The impact of biosimilar competition. 2015. http://ec.europa.eu/DocsRoom/documents/14547/attachments/1/translations/en/renditions/native. Accessed 28 Feb 2016.
- 40.Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefPubMedGoogle Scholar
- 44.••Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in sex Central and Eastern European countries. Eur J Health Econ. 2014;15:S65–71. Budget impact analysis of biosimilar infliximab for rheumatoid arthritis showing significant cost savings and hundreds of additional treated patients in six central and eastern European countries in two different uptake scenarios.CrossRefPubMedGoogle Scholar
- 45.••Jha A, Upton A, Dunlop W, Akehurst R. The budget impact of biosimilar infliximab (Remsima) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32:742–56. Budget impact analysis of biosimilar infliximab in RA, AS, PsA, PsO and IBD showing significant cost savings and hundreds of additional treated patients in five of the biggest European pharmaceutical markets, in three different discount scenarios.CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Lucioni C, Mazzi S, Caporali R. Analisi di budget impact del biosimilare di infliximab: lo scenario italiano. Glob Reg Health Technol Assess. 2015;2(2):78–88.Google Scholar
- 47.Kim J, Hong J, Kudrin A. 5 year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. Arthritis Rheum. 2014;66(Suppl):S512.Google Scholar
- 49.Ruff L, Rezk MF, Uhlig T, Gommers JW. Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis in Europe. Value Health. 2015;18:A639.Google Scholar
- 50.Ruff L, Rezk MF, Uhlig T, Gommers JW. Budget impact analysis of an etanercept biosimilar for the treatment of all licensed etanercept indications for adults in Europe. Value Health. 2015;18:A639.Google Scholar
- 53.Van Arnum P. Biosimilars: market weaknesses and strengths. 2012. http://www.pharmtech.com/biosimilars-market-weaknesses-and-strengths?pageID=1. Accessed 3 Mar 2016.
- 55.IMS Institute for Health Informatics. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. 2011. http://weinberggroup.com/pdfs/Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_biosimiliars_landscape.pdf. Accessed 4 Mar 2016.
- 57.Stanton D. Biosimilar discounts and switching will wipe-out J&J’s Remicade in Norway, says regulator. 2015. http://www.biopharma-reporter.com/Markets-Regulations/Biosimilar-discounts-will-wipe-out-Janssen-s-Remicade-sales-in-Norway. Accessed 10 Mar 2016.
- 58.Rådet for Anvendelse af Dyr Sygehusmedicin. RADS anbefaling vedrørende brug af biosimilært infliximab. 2015. http://www.regioner.dk/medicinsite/rads/behandlingsvejledninger/~/media/EBAF50AB3BA44DE2BF75A03A2F7E83A3.ashx. Accessed 10 Mar 2016.
- 59.Blamont M. Exclusive—Hospira wins French biosimilar drug tender at 45 percent discount. 2015. http://uk.reuters.com/article/uk-france-biosimilars-exclusive-idUKKCN0PD1W320150703. Accessed 11 Mar 2016.
- 60.Kim SC, Choi N-K, Lee J, et al. Uptake of the first biosimilar infliximab since its approval in South Korea. Presented at ACR Annual Meeting, San Francisco, USA; November 2015. Abstract #1273.Google Scholar
- 61.National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 2016. https://www.nice.org.uk/guidance/ta375/chapter/1-Recommendations. Accessed 27 Apr 2016.
- 63.Storvik AG. Huge drug discount astonishes. 2015. http://www.dagensmedisin.no/artikler/2015/01/29/huge-drug-discount-astonishes/. Accessed 2 Feb 2015.